Bambusa Therapeutics, Inc. BBTX
Bambusa Therapeutics, Inc. (Nasdaq: BBTX) is a dermatology drug developer. Its lead program, BBT001, is in Phase 1 for Atopic Dermatitis (moderate-to-severe). Its next catalyst on record is BBT001: Phase 2b AD Study initiation (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BBT001 — Phase 2b AD Study initiation (2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BBT001 | Chronic Spontaneous Urticaria | antibody | Phase 2 |
| BBT002 | CRSwNP | antibody | Phase 2 |
| BBT002 | Asthma | antibody | Phase 2 |
| BBT001 | Atopic Dermatitis | antibody | Phase 1 |
| BBT002 | COPD | antibody | Phase 1 |
| BBT003 | Inflammatory Bowel Disease (Crohn's, UC) | antibody | Pre-clinical |
| BBT004 | Autoantibody-driven Autoimmune Diseases | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 dermatology companies
- Arcutis Biotherapeutics, Inc. ARQT
- Absci Corp ABSI
- FibroBiologics, Inc. FBLG
- Azitra, Inc. AZTR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.